Is Boswellia Recovery Meta-Analysis safe?

The current Migaku evidence database contains 1 reusable source document for Boswellia Recovery Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - 11 12 12 11 13 Current pharmacological treatments provide inconsistent long-term efficacy and are associated with significant side effects []. [Giglio Mariateresa (2025); evidence level 3] - Non-steroidal anti-inflammatory drugs (NSAIDs), though effective for inflammation, offer limited relief in CLBP with neuropathic components and may be associated with gastrointestinal, cardiovascular, and renal complications with prolonged use []. [Giglio Mariateresa (2025); evidence level 3] - Opioids, despite their widespread use, lack evidence for long-term effectiveness in CLBP and pose serious risks, including tolerance, dependence, addiction, and misuse, prompting recommendations for restricted use [,]. [Giglio Mariateresa (2025); evidence level 3] - 1 2 3 4 5 6 7 8 9 2 10 Low back pain is a leading cause of disability worldwide, affecting approximately 619 million people globally in 2020, with projections indicating that this number could rise to 843 million by 2050 []. [Giglio Mariateresa (2025); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.